Brief: TCR2 Therapeutics To Announce Results From Ongoing Phase 1/2 Trial Of Gavo-Cel In Mesothelin-Expressing Solid Tumors
13/09/2021 11:58
Sept 13 (Reuters) - TCR2 Therapeutics Inc TCRR.O :
* TCR2 THERAPEUTICS TO ANNOUNCE EXTENDED RESULTS FROM
ONGOING
PHASE 1/2 TRIAL OF GAVO-CEL IN MESOTHELIN-EXPRESSING SOLID
TUMORS
Source text for Eikon: ID:nGNX6KvWN5
Further company coverage: TCRR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TCR2 Therapeutics
See all newsBrief: TCR2 Therapeutics Entered Into An Assignment Of Lease Agreement With Astrazeneca
TCR2 Therapeutics falls on bigger-than-expected Q1 loss
Brief: Tcr² Therapeutics Reports Q1 2023 Financial Results And Provides Corporate Update
TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
TCR2 Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview